CO2024004227A2 - Métodos y composiciones para el tratamiento de la enfermedad renal poliquística - Google Patents

Métodos y composiciones para el tratamiento de la enfermedad renal poliquística

Info

Publication number
CO2024004227A2
CO2024004227A2 CONC2024/0004227A CO2024004227A CO2024004227A2 CO 2024004227 A2 CO2024004227 A2 CO 2024004227A2 CO 2024004227 A CO2024004227 A CO 2024004227A CO 2024004227 A2 CO2024004227 A2 CO 2024004227A2
Authority
CO
Colombia
Prior art keywords
kidney disease
polycystic kidney
treatment
methods
compositions
Prior art date
Application number
CONC2024/0004227A
Other languages
English (en)
Inventor
Denis Drygin
Garth A Kinberger
Edmund Chun Yu Lee
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of CO2024004227A2 publication Critical patent/CO2024004227A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se proporcionan métodos para el tratamiento de la enfermedad renal poliquística, incluida la enfermedad renal poliquística autosómica dominante, utilizando oligonucleótidos modificados dirigidos a miR-17.
CONC2024/0004227A 2021-10-08 2024-04-05 Métodos y composiciones para el tratamiento de la enfermedad renal poliquística CO2024004227A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163253933P 2021-10-08 2021-10-08
PCT/US2022/077766 WO2023060237A1 (en) 2021-10-08 2022-10-07 Methods and compositions for treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
CO2024004227A2 true CO2024004227A2 (es) 2024-04-18

Family

ID=84246040

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0004227A CO2024004227A2 (es) 2021-10-08 2024-04-05 Métodos y composiciones para el tratamiento de la enfermedad renal poliquística

Country Status (11)

Country Link
EP (1) EP4413132A1 (es)
KR (1) KR20240073028A (es)
CN (1) CN118103510A (es)
AR (1) AR127325A1 (es)
AU (1) AU2022361062A1 (es)
CA (1) CA3234547A1 (es)
CO (1) CO2024004227A2 (es)
IL (1) IL311734A (es)
MX (1) MX2024003529A (es)
TW (1) TW202320808A (es)
WO (1) WO2023060237A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
ES2611924T3 (es) 2006-10-03 2017-05-11 Arbutus Biopharma Corporation Formulaciones que contienen lípidos
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
SG10201803157XA (en) * 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
TWI769197B (zh) * 2016-12-05 2022-07-01 美商雷格勒斯治療公司 用於治療多囊腎病之組成物
EP3548011B1 (en) * 2016-12-05 2023-06-14 Regulus Therapeutics Inc. Methods for treatment of polycystic kidney disease

Also Published As

Publication number Publication date
IL311734A (en) 2024-05-01
CA3234547A1 (en) 2023-04-13
CN118103510A (zh) 2024-05-28
EP4413132A1 (en) 2024-08-14
AR127325A1 (es) 2024-01-10
MX2024003529A (es) 2024-04-01
AU2022361062A1 (en) 2024-03-21
WO2023060237A1 (en) 2023-04-13
KR20240073028A (ko) 2024-05-24
TW202320808A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY37146A (es) Ligandos de direccionamiento para compuestos terapéuticos
CL2018002359A1 (es) Métodos para usar agonistas de fxr
UY37145A (es) Ligandos de direccionamiento
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
UY37205A (es) Inhibidores de bromodominios
BR112022003505A2 (pt) Composições e métodos para tratamento de distúrbios associados a dna repetitivo
EA201991360A1 (ru) Модифицированные олигонуклеотиды для лечения поликистозной болезни почек
ES2380951T3 (es) Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CL2019001526A1 (es) Métodos para el tratamiento de la enfermedad renal poliquística.
EP4268891A3 (en) Compound for use in methods for treatment of polycystic kidney disease
UY38352A (es) Inhibidores de integrina alfavbeta6
DOP2011000053A (es) Agentes antifungicos
BR112023000350A2 (pt) Sais e formas de um inibidor de wee1
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
BR112022024747A2 (pt) Composições e métodos para edição de epigenoma
CO2024004227A2 (es) Métodos y composiciones para el tratamiento de la enfermedad renal poliquística
UY4891S (es) Calzado
PH12020551206A1 (en) Farber disease markers and uses thereof
EA202193121A1 (ru) Лечение рака
BR112022012283A2 (pt) Combinações